These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11224654)

  • 21. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy.
    Aldámiz-Echevarría L; Prieto JA; Andrade F; Elorz J; Sojo A; Lage S; Sanjurjo P; Vázquez C; Rodríguez-Soriano J
    Pediatr Res; 2009 Nov; 66(5):585-9. PubMed ID: 19851226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis.
    Strandvik B; Gronowitz E; Enlund F; Martinsson T; Wahlström J
    J Pediatr; 2001 Nov; 139(5):650-5. PubMed ID: 11713441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation.
    Lloyd-Still JD; Johnson SB; Holman RT
    Am J Clin Nutr; 1981 Jan; 34(1):1-7. PubMed ID: 7446449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cystic fibrosis, fatty acid imbalance, ceramide and lipid rafts].
    Chanson M
    Arch Pediatr; 2009 Jun; 16(6):543-5. PubMed ID: 19541078
    [No Abstract]   [Full Text] [Related]  

  • 25. Abnormal fatty-acid composition of plasma-lipids in cystic fibrosis. A primary or a secondary defect?
    Hubbard VS; Dunn GD; di Sant'Agnese PA
    Lancet; 1977 Dec 24-31; 2(8052-8053):1302-4. PubMed ID: 74723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study.
    Durieu I; Vericel E; Guichardant D; Roth H; Steghens JP; Drai J; Josserand RN; Fontaine E; Lagarde M; Bellon G
    J Cyst Fibros; 2007 Sep; 6(5):320-6. PubMed ID: 17257908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothesis: vitamin E complements polyunsaturated fatty acids in essential fatty acid deficiency in cystic fibrosis.
    Wood LG; Fitzgerald DA; Garg ML
    J Am Coll Nutr; 2003 Aug; 22(4):253-7. PubMed ID: 12897038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients.
    Morin C; Cantin AM; Vézina FA; Fortin S
    Mar Drugs; 2018 May; 16(6):. PubMed ID: 29861448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis.
    Olveira G; Olveira C; Acosta E; Espíldora F; Garrido-Sánchez L; García-Escobar E; Rojo-Martínez G; Gonzalo M; Soriguer F
    Arch Bronconeumol; 2010 Feb; 46(2):70-7. PubMed ID: 20045240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts.
    Benabdeslam H; Garcia I; Bellon G; Gilly R; Revol A
    Am J Clin Nutr; 1998 May; 67(5):912-8. PubMed ID: 9583849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum fatty acid profiles in cystic fibrosis patients and their parents.
    Christophe AB; Warwick WJ; Holman RT
    Lipids; 1994 Aug; 29(8):569-75. PubMed ID: 7990664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?
    Scambi C; Guarini P; De Franceschi L; Bambara LM
    J Cyst Fibros; 2006 Aug; 5(3):197-9. PubMed ID: 16516563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients.
    Van Biervliet S; Vanbillemont G; Van Biervliet JP; Declercq D; Robberecht E; Christophe A
    Ann Nutr Metab; 2007; 51(6):541-9. PubMed ID: 18227622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Status of plasma and erythrocyte fatty acids and vitamin A and E in young children with cystic fibrosis.
    Biggemann B; Laryea MD; Schuster A; Griese M; Reinhardt D; Bremer HJ
    Scand J Gastroenterol Suppl; 1988; 143():135-41. PubMed ID: 3164500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis.
    Rettammel AL; Marcus MS; Farrell PM; Sondel SA; Koscik RE; Mischler EH
    J Am Diet Assoc; 1995 Apr; 95(4):454-9. PubMed ID: 7699188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eicosanoids in cystic fibrosis.
    Kida Y
    N Engl J Med; 2004 May; 350(19):2000-1; author reply 2000-1. PubMed ID: 15128902
    [No Abstract]   [Full Text] [Related]  

  • 37. [Plasma fatty acids in children with cystic fibrosis].
    Lázaro Almarza A; Tosao Sánchez A; Sarriá Chueca A; Oliván Gonzalvo G; Adiego Leza MI; Bueno Sánchez M
    An Esp Pediatr; 1989 Nov; 31(5):440-2. PubMed ID: 2515782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a newly developed fat emulsion containing eicosapentaenoic acid and docosahexaenoic acid on fatty acid profiles in rats.
    Tashiro T; Yamamori H; Hayashi N; Sugiura T; Takagi K; Furukawa K; Nakajima N; Itoh I; Wakabayashi T; Ohba S; Akahane N
    Nutrition; 1998 Apr; 14(4):372-5. PubMed ID: 9591310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients.
    Wood LG; Fitzgerald DA; Gibson PG; Cooper DM; Garg ML
    Am J Clin Nutr; 2002 Apr; 75(4):668-75. PubMed ID: 11916752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health benefits of docosahexaenoic acid (DHA).
    Horrocks LA; Yeo YK
    Pharmacol Res; 1999 Sep; 40(3):211-25. PubMed ID: 10479465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.